Compare Nuwellis Inc (NUWE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Zoetis Inc — how do they compare? Nuwellis Inc trades at $1.42 (market cap $542.80K), while Zoetis Inc trades at $72.99 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 57369.2× Nuwellis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | ZTS | |
|---|---|---|
Market Cap | $542.80K | $31.14B |
Sector | Technology | Health |
52-Week High | $220.50 | $156.76 |
52-Week Low | $1.42 | $71.91 |
Enterprise Value | -$1.27M | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
